PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges
Open Access
Abstract
Poly(ADP-ribose) polymerase inhibitors (PARPi) have reshaped therapy for advanced prostate cancer, yet durable benefit remains concentrated in BRCA1/2-altered tumors, especially BRCA2, and most responders eventually relapse. Here, we frame PARPi response and resistance through a unifying model in which DNA damage response (DDR) rewiring (e.g., homologous recombination repair (HRR) restoration, fork protection, checkpoint tolerance, and altered drug handling) converges with treatment-induced dormancy and quiescent therapy-tolerant residual states that sustain minimal residual disease (MRD) under androgen receptor pathway inhibition (ARPI) and PARP blockade. We synthesize clinical and translational evidence for PARPi monotherapy and PARPi-based combinations across disease states. In first-line metastatic castration-resistant prostate cancer (mCRPC), PARPi plus ARPI consistently prolongs radiographic progression-free survival, with the greatest benefit in HRR-altered tumors, and emerging overall-survival signals in selected subgroups. In later-line settings, monotherapy activity is most robust in BRCA2-mutated disease, whereas non-BRCA HRR alterations show heterogeneous and often modest responses, underscoring the need for biomarkers beyond gene panels. We also discuss combination strategies with DDR-targeting agents, radioligand therapies, and immunotherapy, and summarize ongoing phase III programs in metastatic castration-sensitive prostate cancer (mCSPC). Finally, we outline practical considerations for biomarker-informed patient selection, monitoring, sequencing, and toxicity management, with particular emphasis on intercepting MRD and resistance evolution.Keywords
Funding Information
- Pacific Northwest Prostate Cancer SPORE (P50 CA097186)
- Terry Fox Research Institute (#1109)
- Battle Creek Community Foundation (#PRRG012)
This publication has 91 references indexed in Scilit:
- Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancerCell Reports, 2025
- Elucidating acquired PARP inhibitor resistance in advanced prostate cancerCancer Cell, 2024
- First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesCancer Treatment Reviews, 2024
- Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissueBreast Cancer Research and Treatment, 2023
- The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancerEuropean Journal of Cancer, 2023
- Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialAnnals of Oncology, 2023
- Pilot Study: PARP1 Imaging in Advanced Prostate CancerMolecular Imaging and Biology, 2022
- Persistent Cancer Cells: The Deadly SurvivorsCell, 2020
- A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2Cancer Cell, 2012
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11Cell, 2011